NCT04493060 2025-08-07Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic CancerMayo ClinicPhase 2 Completed22 enrolled 17 charts
NCT04164069 2024-12-27Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without BevacizumabOhio State University Comprehensive Cancer CenterPhase 1 Completed9 enrolled